Response to Comment on: Winkler et al. Histone Deacetylase 6 (HDAC6) Is an Essential Modifier of Glucocorticoid-Induced Hepatic Gluconeogenesis. Diabetes 2012;61:513–523

  1. Ulrich Kintscher
  1. Institute of Pharmacology, Charité Medical University, Center for Cardiovascular Research, Berlin, Germany
  1. Corresponding author: Ulrich Kintscher, ulrich.kintscher{at}charite.de.

In his letter (1), Mahla proposes the combination therapy of histone deacetylase 6 (HDAC6) and heat shock protein 90 (HSP90) inhibitors as an antitumor strategy. This proposal is based on previous publications demonstrating that HDAC6 deacetylates HSP90, thereby modulating the activity of HSP90 client proteins. Pharmacological inhibition of HSP90 has been shown to serve as a potential anticancer approach. In addition, HDAC6 regulates multiple pathways involved in tumorigenesis, and HDAC6 inhibitors are currently developed for …

No Related Web Pages
| Table of Contents
OPEN ACCESS ARTICLE

This Article

  1. doi: 10.2337/db12-0474 Diabetes vol. 61 no. 7 e11
  1. Free via Open Access: OA